Study type: Human research · Status: Verified against declared source
Role of LL-37 in thrombotic complications in patients with COVID-19.
Cellular and molecular life sciences : CMLS · 2022
Study scale: All human specimens and clinical information were collected with informed consent of the patients prior to the study from the Chongqing Public Health Medical Center (CPHMC) and Department of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medial University).
Abstract only: Open source record
Product or molecular entity relationships
- LL-37: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
Not reported in the reviewed source.
Methods
The online version contains supplementary material available at 10.1007/s00018-022-04309-y.
Scale or participants
All human specimens and clinical information were collected with informed consent of the patients prior to the study from the Chongqing Public Health Medical Center (CPHMC) and Department of Infectious Diseases, Southwest Hospital, Third Military Medical University (Army Medial University).
Key findings
Blood clot formation induced by dysfunctional coagulation is a frequent complication of coronavirus disease 2019 (COVID-19) and a high-risk factor for severe illness and death.
Limitations and uncertainty
Blood clot formation induced by dysfunctional coagulation is a frequent complication of coronavirus disease 2019 (COVID-19) and a high-risk factor for severe illness and death.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.